Pharmaceutical Market Europe • February 2026 • 40

APPOINTMENTS

Eli Lilly

Adrienne Brown

Image

Eli Lilly has appointed Adrienne Brown as Executive Vice President and President of Lilly Immunology, joining the Executive Committee. Brown has spent more than 20 years at Lilly, most recently in the role of Group Vice President & Head of Corporate Business Development. Other roles formerly held by Brown at Lilly include Group Vice President & Head of US Diabetes & Obesity Business Unit and Marketing Director, US Diabetes, with Brown leading the US launch of the weight loss treatment Mounjaro. During her time at Lilly, Brown has gained increasing responsibility in the key markets of Japan and the US. She has also built her expertise in areas including business development, sales, marketing and commercial strategy.

Eli Lilly

Jacob Van Naarden

Image

Eli Lilly has appointed Jacob Van Naarden as Executive Vice President and President of Lilly Oncology. Van Naarden has worked at Lilly since 2019, following its acquisition of Loxo Oncology, where he served for over 11 years and held roles including CEO, Chief Operating Officer and Chief Business Officer.

Eli Lilly

Daniel Skovronsky

Image

Eli Lilly has appointed Daniel Skovronsky as Chief Scientific and Product Officer and President of Lilly Research Laboratories. Skovronsky has worked at Lilly since its acquisition of Avid Radiopharmaceuticals, where he was CEO, in 2010. In his new role he will guide product strategy for Cardiometabolic Health, Immunology and Neuroscience.

CelLBxHealth

Peter Collins

Image

CelLBxHealth has appointed Peter Collins as CEO. He was previously CEO of SAGA Diagnostics, where he served for over four years. Other roles formerly held by Collins include Chief Business Officer at Inivata and Yourgene Health, Vice President Head of Diagnostics at GlaxoSmithKline and Independent Director of miDiagnostics.

Angelini Pharma

Sergio Marullo
di Condojanni

Image

Angelini Pharma has appointed Sergio Marullo di Condojanni as CEO. Marullo di Condojanni has already served as CEO of Angelini Industries since 2020. In addition to his seven years at Angelini Industries, he holds directorial and advisory roles at a number of companies, including Angelini Technologies, Banca Aletti and B20 Italy.

Ipsen

Pierrick Lefranc

Ipsen has appointed Pierrick Lefranc as Executive Vice President Technical Operations and a member of its Executive Leadership Team. Lefranc joined Ipsen in 2013 and has held roles including Head of the company’s Signes site and Senior Vice President. He was also previously Director of Industrial Operations at Stallergenes.

Syncromune

Stephen Dale

Syncromune has appointed Dr Stephen Dale as Chief Medical Officer. Dale most recently served as Head of R&D and Chief Medical Officer at Kura Oncology. He has also held senior roles at Kyowa Kirin and AstraZeneca. His work in clinical development and translational strategy have contributed to various regulatory approvals during his career.

Human Continuum

Omar Khalid Sial

Human Continuum has appointed Dr Omar Khalid Sial as Chief Scientific Officer. Sial previously held the position of postdoctoral associate at the University of Florida Scripps Biomedical Research Institute. Other previous experience includes research work at the Icahn School of Medicine, Mount Sinai and consultancy work at Stream Biomedical.

Angelini Pharma

Roberto Scrivo

Angelini Pharma has appointed Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer. Scrivo was previously Chief of Public Affairs and Corporate Communications and Sustainability Officer at the Engineering Group. Other former roles include Public Affairs Senior Director at Sky Italia and Head of Public Affairs at Fastweb.